Wilson M. Compton, MD, MPE; Eric M. Wargo, PhD
Disclaimer: The opinions expressed in this commentary are those of the authors and do not necessarily reflect the views of the National Institute on Drug Abuse, the National Institutes of Health, or the U.S. Department of Health and Human Services.
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-0883.
Requests for Single Reprints: Wilson M. Compton, MD, MPE, 6001 Executive Boulevard, MSC 9581, Bethesda, MD 20892; e-mail, email@example.com.
Current Author Addresses: Dr. Compton: 6001 Executive Boulevard, MSC 9581, Bethesda, MD 20892.
Dr. Wargo: National Institute on Drug Abuse, 6001 Executive Boulevard, Bethesda, MD 20892.
Compton WM, Wargo EM. Prescription Drug Monitoring Programs: Promising Practices in Need of Refinement. Ann Intern Med. 2018;168:826–827. [Epub ahead of print 8 May 2018]. doi: https://doi.org/10.7326/M18-0883
Download citation file:
Published: Ann Intern Med. 2018;168(11):826-827.
Published at www.annals.org on 8 May 2018
Emergency Medicine, Tobacco, Alcohol, and Other Substance Abuse.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use